Side-by-side · Research reference

AdipotidevsGHK-Cu

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED15/49 cited

BHuman-MechanisticHUMAN-REVIEWED8/47 cited

Adipotide

Pro-apoptotic Vascular-Targeting Peptide · Preclinical Only

PreclinicalStatus

PHB1TargetHossen 2013

ApoptosisMechanismHossen 2013

IV · Systemic · Preclinical Protocols OnlyHossen 2013

GHK-Cu

Tripeptide · Skin / Hair / Wound Healing

1–2 mgSQ dosePickart 2018

HumanMechanisticPickart 2018 Zink 2003

HoursHalf-life

SQ or topical · Local · Daily or 2-3×/week

01Mechanism of Action

Parameter

Adipotide

GHK-Cu

Primary target

Prohibitin-1 (PHB1) on adipose vasculature endotheliumHossen 2013

Copper-dependent enzymes (lysyl oxidase, SOD); regulator of >4000 human genesPickart 2018

Pathway

CKGGRAKDC domain binds PHB1 → Peptide internalisation → D(KLAKLAK)₂ mitochondrial membrane disruption

Cu(II) delivery via GHK chelation → ↑collagen / elastin / GAG synthesis; ↓inflammatory cytokines; ↑hair follicle growth-factor signalingPickart 2018

Downstream effect

Endothelial apoptosis → Adipose vascular collapse → Adipocyte involution → Weight loss

Skin firmness + texture improvement, accelerated wound healing, hair regrowth, anti-inflammatory actionPickart 2018 Zink 2003

Feedback intact?

N/A — Direct apoptotic mechanism, non-hormonal

Replaces declining endogenous levels

Origin

Synthetic bioconjugate: PHB1-targeting homing peptide + pro-apoptotic KLA sequence

Endogenous tripeptide first isolated from human plasma; declines from ~200 ng/mL at age 20 to ~80 ng/mL at age 60Pickart 2018

Antibody development

—

02Dosage Protocols

Parameter

Adipotide

GHK-Cu

Animal dose (mouse)

Low dose (not specified in abstract)Hossen 2013

Systemic injection in diet-induced obesity (DIO) models.Hossen 2013

—

Route

Intravenous (systemic injection)

—

Frequency

Not specified in available data

Daily or 2–3× per week (SQ)

Evidence basis

Preclinical animal models only

Human-mechanistic + topical clinical studiesPickart 2018

Human data

None — no clinical trials reported

—

Standard SQ dose

—

1–2 mg / dayPickart 2018

Anecdotal injectable range; topical creams use 0.1–2% solutions.

Topical concentration

—

0.1–2.0% in serum / cream

Lower / starter dose

—

0.5 mg / day SQ

Duration

—

8–12 weeks for visible skin / hair effect

Reconstitution

—

Bacteriostatic water; light-protected

Timing

—

No specific time; evening preferred for topicals

Half-life

—

Hours (estimated; rapid tissue uptake)

03Metabolic / Fat Loss Evidence

Parameter

Adipotide

GHK-Cu

Primary fat target

White adipose tissue (all depots)

—

Mechanism

Vascular apoptosis → adipose blood supply collapse → adipocyte deathHossen 2013

—

Body weight reduction

Significant reduction in DIO miceHossen 2013

Absolute values not provided in abstract.

—

Leptin levels

Significant decrease

Parallel to adipose mass reduction.

—

Effect on adipocytes

Antiobesity effect on dysfunctional adipose cells (adipocytes + macrophages)Hossen 2013

—

Ectopic fat

Reduction in ectopic fat depositionHossen 2013

Marker of dysfunctional adipose tissue / metabolic syndrome.

—

Species tested

Obese rhesus monkeys, DIO mice

—

Human translation

Unknown — no clinical trials

—

04Side Effects & Safety

Parameter

Adipotide

GHK-Cu

Safety profile

Unknown — preclinical data only

—

Vascular selectivity

Targets adipose vasculature; off-target vascular effects unknown

—

Apoptotic mechanism risk

Pro-apoptotic payload may affect unintended tissues if selectivity incomplete

—

Kidney / liver toxicity

Not reported in available data

—

Immunogenicity

Not assessed in available data

—

Injection site reaction

—

Erythema, mild pruritus (common)

Topical irritation

—

Mild redness, transient stinging

Copper accumulation

—

Theoretical with very high chronic doses

Allergic reaction

—

Rare hypersensitivity to copper

Pregnancy / OB

—

Avoid topical and SQ — insufficient data

Wilson disease

—

Contraindicated

Absolute Contraindications

Adipotide

·Human use — not approved, no clinical safety data

GHK-Cu

·Wilson disease (copper-overload disorder)
·Pregnancy / breastfeeding
·Known copper hypersensitivity

Relative Contraindications

Adipotide

·Any condition requiring intact adipose-tissue vascularisation

GHK-Cu

·Hemochromatosis (copper-iron crosstalk theoretical)
·Concurrent copper-chelator therapy

05Administration Protocol

Parameter

Adipotide

GHK-Cu

1. Route

Intravenous injection (systemic) in preclinical models. No human protocols exist.

Add 1–2 mL bacteriostatic water to a 50 mg vial → 25–50 mg/mL. Use within 30 days, refrigerated.

2. Formulation

Bioconjugate peptide. May also be encapsulated in nanoparticles (prohibitin-targeted nanoparticle formulation, KLA-PTNP, showed superior efficacy vs. free bioconjugate in mice).Hossen 2013

SQ — local to the area of interest (face, scalp) for skin / hair indications. Rotate sites.

3. Preclinical dosing

Low-dose systemic injection (exact dosing not specified in available abstract). Frequency and duration not detailed.Hossen 2013

Anytime; evening preferred. Topical: apply to clean dry skin.

4. Storage

Not specified — likely requires peptide-grade lyophilised storage and reconstitution.

Lyophilised: room temp, light-protected. Reconstituted: refrigerate, light-protected, ≤30 days.

5. Needle

—

30–31G, short (4–6 mm) for shallow SQ. Topical: clean fingertips, no needle.

06Stack Synergy

Adipotide

— no documented stacks

GHK-Cu

+ BPC-157

Moderate

View BPC-157 →

GHK-Cu drives ECM remodelling and copper-dependent enzymes; BPC-157 upregulates VEGFR2 angiogenesis and fibroblast migration. The pathways are non-overlapping and complementary — together they accelerate wound healing more than either alone in anecdotal protocols.

GHK-Cu: 1–2 mg SQ · daily near wound
BPC-157: 250–500 mcg SQ · daily near wound
Primary benefit: Combined ECM rebuilding + angiogenesis for tissue repair